Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 99 : 1 2 3 4 5 Next »

Recs

0
Member Avatar OklaBoston (69.28) Submitted: 11/20/2014 11:08:39 PM : Underperform Start Price: $305.28 BIIB Score: +0.12

Topping out and should never have gotten above $200, let alone $300

Recs

0
Member Avatar Orffy (61.11) Submitted: 11/20/2014 4:17:10 AM : Outperform Start Price: $300.10 BIIB Score: -0.05

Multiple Sclerosis (MS) is a horrible disease that particularly plagues people living in the Northern Hemisphere (especially North America and Northern Europe). MS is a significant problem that will result in a significant reward for those who can solve its complexities. As of now, the disease has no cure, which means that companies with current research into this disease have an edge on discovering any potential cures. This could be worth many billions of dollars in cash flows for the companies that can accomplish this feat. Biogen Idec has proven itself capable of building effective MS drugs that doctors trust and recommend. With their successful track record and great financials, I see no reason to bet against Biogen Idec. Long-term.

Recs

0
Member Avatar RugbyViking13 (88.52) Submitted: 10/22/2014 9:00:16 PM : Outperform Start Price: $314.00 BIIB Score: -9.58

Staggering numbers from this bio tech company

Recs

0
Member Avatar billmans (< 20) Submitted: 10/22/2014 7:44:45 AM : Outperform Start Price: $300.00 BIIB Score: -5.17

Pipeline!

Recs

0
Member Avatar racoveanul (80.43) Submitted: 7/11/2014 10:17:42 AM : Outperform Start Price: $318.14 BIIB Score: -9.90

I expect at least a point a week from this stock, for the next five years.

Recs

0
Member Avatar Flygal5 (99.06) Submitted: 7/8/2014 6:47:19 PM : Outperform Start Price: $322.62 BIIB Score: -11.03

Cancer drugs and new MS drug

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $295.63 BIIB Score: -6.91

4 Big Elderly. Reeves.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:59:02 PM : Outperform Start Price: $320.20 BIIB Score: -15.92

BIIB and GILD are my 2 top holdings. In the long term, this is a no brainer. Very stacked pipeline.

Recs

0
Member Avatar yooperking (47.78) Submitted: 4/2/2014 10:50:16 AM : Outperform Start Price: $312.75 BIIB Score: -12.49

PEG ratio of 1.5, Quarterly revenue growth (yoy) or 38.6% and Quarterly earnings growth (yoy) of 56.5% makes this company's stock a good buy. Institutional ownership of 94.5%, 0.9% insider ownership and a 1.9 short ratio leaves room for more buyers.

Recs

0
Member Avatar TerryFool (43.31) Submitted: 3/10/2014 8:31:23 PM : Outperform Start Price: $297.84 BIIB Score: -10.48

EPS 1YR 25% 2YR 20% 5YR 18%

Recs

0
Member Avatar RideWildfire (38.42) Submitted: 2/11/2014 11:07:00 AM : Outperform Start Price: $315.77 BIIB Score: -18.26

They are delivering relief to a large population in ways that lead their competitors.

Recs

0
Member Avatar TerryHoodSr (59.59) Submitted: 7/21/2013 1:30:37 AM : Outperform Start Price: $289.85 BIIB Score: -5.40

growth

Recs

1
Member Avatar sugarmag23 (< 20) Submitted: 6/5/2013 11:47:30 AM : Outperform Start Price: $215.34 BIIB Score: +13.62

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

Recs

1
Member Avatar bear713 (< 20) Submitted: 5/22/2013 11:18:31 AM : Outperform Start Price: $236.36 BIIB Score: +5.57

This pharmaceutical company has a well defined niche market and a proven track record of inovation.

Recs

1
Member Avatar elv1659 (< 20) Submitted: 4/9/2013 12:24:42 PM : Outperform Start Price: $192.92 BIIB Score: +25.50

Have a new pill for MS. Before patients had to take infusions. Much easier to administer and control disease.

Recs

1
Member Avatar Phuman2 (< 20) Submitted: 4/9/2013 8:54:25 AM : Outperform Start Price: $194.51 BIIB Score: +24.09

Steady growth and high profit margins

Recs

0
Member Avatar FutureMonkey (81.66) Submitted: 3/2/2013 2:57:41 PM : Outperform Start Price: $167.64 BIIB Score: +45.07

Top 25 pick

Recs

0
Member Avatar 42asdf (55.68) Submitted: 3/1/2013 4:50:40 PM : Outperform Start Price: $167.64 BIIB Score: +45.07

has great growth, profit margins, and financial health. While it's p/e is fairly high (28.9), it is lower than the industry average (45.2).

Recs

0
Member Avatar NHWeston102 (64.57) Submitted: 2/7/2013 11:47:24 AM : Outperform Start Price: $159.11 BIIB Score: +53.27

If you can't develop a ground-breaker, buy one!! Tysabri will do BIIB good!

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 4:57:02 PM : Underperform Start Price: $156.15 BIIB Score: -57.14

Nasdaq in maximums.

Results 1 - 20 of 99 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement